<p>Fluent Financial LLC 在第三季度购买了 Biogen Inc.（NASDAQ:BIIB - 免费报告）的新股份，根据其最近向证券交易委员会（SEC）提交的文件。该基金购买了 25,543 股该生物技术公司的股票，价值约为 3,578,000 美元。Biogen 占 Fluent Financial LLC 持有的股份的 1.4%，使其成为该基金第 23 大持仓。</p>
<ul>
<li>Biogen 股票正在转变为价值投资</li>
</ul>
<p>其他几家机构投资者也对该股票的持仓进行了调整。Elevation Point Wealth Partners LLC 在第二季度收购了价值约 25,000 美元的 Biogen 新股份。Rothschild Investment LLC 在第二季度将其在 Biogen 股票中的持仓提高了 64.7%。Rothschild Investment LLC 目前拥有 224 股该生物技术公司的股票，价值 28,000 美元，此前在此期间又收购了 88 股。Concord Wealth Partners 在第二季度将其在 Biogen 股票中的持仓提高了 100.0%。Concord Wealth Partners 目前拥有 228 股该生物技术公司的股票，价值 29,000 美元，此前在此期间又收购了 114 股。NewSquare Capital LLC 在第二季度将其在 Biogen 股票中的持仓增加了 134.6%。NewSquare Capital LLC 目前拥有 244 股该生物技术公司的股票，价值 31,000 美元，此前在上个季度又购买了 140 股。最后，WFA of San Diego LLC 在第二季度购买了价值 32,000 美元的 Biogen 新股份。目前，87.93% 的股票由机构投资者持有。</p>
<h2>Biogen 价格表现</h2>
<p>BIIB 股票在周五开盘价为 174.80 美元。该股票的市值为 256.4 亿美元，市盈率为 15.93，市盈增长比率为 1.47，贝塔值为 0.13。该公司的债务与股本比率为 0.35，流动比率为 2.72，速动比率为 2.04。该公司的 50 日简单移动平均线为 163.65 美元，200 日简单移动平均线为 145.29 美元。Biogen Inc. 的一年低点为 110.04 美元，一年高点为 185.17 美元。</p>
<ul>
<li>这 3 只股票被严重低估：抓住机会</li>
</ul>
<p>Biogen（NASDAQ:BIIB - 获取免费报告）最近在 10 月 30 日星期四发布了其财报。该生物技术公司报告本季度每股收益为 4.81 美元，超出分析师一致预期的 3.89 美元，超出幅度为 0.92 美元。该公司本季度的收入为 25.3 亿美元，而分析师预期为 23.4 亿美元。Biogen 的净利润率为 15.98%，股本回报率为 14.13%。该公司的收入同比增长 2.8%。在去年同期，该公司每股收益为 4.08 美元。Biogen 已将其 2025 财年的指导目标设定为每股收益 14.500-15.00。研究分析师预计 Biogen Inc. 本财年将发布每股收益 15.83。</p>
<h2>分析师评级变动</h2>
<p>多家券商对 BIIB 发布了报告。汇丰银行在 12 月 10 日的研究报告中重申了 &#34;减持&#34; 评级，并将 Biogen 股票的目标价设定为 143.00 美元（下调自 144.00 美元）。杰富瑞金融集团在 11 月 28 日的报告中将 Biogen 股票的目标价从 190.00 美元上调至 210.00 美元，并给予该股票 &#34;买入&#34; 评级。瑞穗证券在 11 月 3 日的研究报告中将 Biogen 股票的目标价从 169.00 美元上调至 177.00 美元，并给予该公司 &#34;跑赢大盘&#34; 评级。罗伯特·贝尔德在 10 月 31 日的研究报告中将 Biogen 股票的目标价从 255.00 美元下调至 250.00 美元。最后，BMO Capital Markets 在周四将 Biogen 的目标价从 150.00 美元上调至 165.00 美元，并给予该公司 &#34;市场表现&#34; 评级。十位股票研究分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Biogen 目前的共识评级为 &#34;持有&#34;，平均目标价为 183.08 美元。</p>
<ul>
<li>阿尔茨海默病药物股票：投资于 Eli Lilly、Biogen、Roche</li>
</ul>
<p><strong>查看我们最新的 Biogen 股票报告</strong></p>
<h2>关于 Biogen</h2>
<p>（免费报告）</p>
<p>Biogen Inc 是一家跨国生物技术公司，专注于发现、开发和提供神经系统及神经退行性疾病的治疗方案。公司总部位于马萨诸塞州剑桥，长期以来专注于神经科学，研究和商业活动涵盖多种治疗领域，包括多发性硬化症、脊髓性肌萎缩症和阿尔茨海默病。Biogen 成立于 1978 年，已发展成为一家全球生物制药公司，在北美、欧洲、日本及其他国际市场拥有业务和商业存在。</p>
<p>该公司的市场产品组合历史上包括几种知名的多发性硬化症治疗药物，如 Avonex、Tysabri 和 Tecfidera，并且还在追求针对罕见神经疾病和遗传性神经肌肉疾病的治疗。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Biogen 更好</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>这 3 家银行正在年末反弹，但这种趋势会持续吗？</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>3 只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>3 家杂货股票证明它们仍然是必需品</li>
<li>该 ETF 在美联储降息后获得了重大顺风</li>
</ul>
<p><strong>想看看其他对 BIIB 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Biogen Inc.（NASDAQ:BIIB - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Biogen 吗？</h2>
<p>在你考虑 Biogen 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Biogen 并不在名单上。</p>
<p>虽然 Biogen 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BIIB

<p>Fluent Financial LLC 已经收购了 Biogen Inc. 的新股份，购买了 25,543 股，价值约为 358 万美元。这项投资使 Biogen 成为 Fluent Financial 投资组合中第 23 大的持仓。Biogen 的股票表现和分析师评级也得到了强调，普遍评级为 “持有”，平均目标价为 183.08 美元。该公司专注于神经疾病的治疗，并在生物技术领域具有重要地位</p>

<p>Fluent Financial LLC purchased a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 25,543 shares of the biotechnology company's stock, valued at approximately $3,578,000. Biogen makes up 1.4% of Fluent Financial LLC's holdings, making the stock its 23rd largest position.</p>
<div class="lb-trans"><p>Fluent Financial LLC 在第三季度购买了 Biogen Inc.（NASDAQ:BIIB - 免费报告）的新股份，根据其最近向证券交易委员会（SEC）提交的文件。该基金购买了 25,543 股该生物技术公司的股票，价值约为 3,578,000 美元。Biogen 占 Fluent Financial LLC 持有的股份的 1.4%，使其成为该基金第 23 大持仓。</p>
</div><ul>
<li>Biogen Stock Is Mutating Into a Value Play</li>
</ul>
<div class="lb-trans"><ul>
<li>Biogen 股票正在转变为价值投资</li>
</ul>
</div><p>Several other institutional investors have also made changes to their positions in the stock. Elevation Point Wealth Partners LLC acquired a new stake in Biogen during the second quarter worth approximately $25,000. Rothschild Investment LLC lifted its position in shares of Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 88 shares during the period. Concord Wealth Partners lifted its position in shares of Biogen by 100.0% during the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 114 shares during the period. NewSquare Capital LLC grew its holdings in shares of Biogen by 134.6% during the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 140 shares in the last quarter. Finally, WFA of San Diego LLC bought a new position in shares of Biogen in the second quarter worth $32,000. 87.93% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者也对该股票的持仓进行了调整。Elevation Point Wealth Partners LLC 在第二季度收购了价值约 25,000 美元的 Biogen 新股份。Rothschild Investment LLC 在第二季度将其在 Biogen 股票中的持仓提高了 64.7%。Rothschild Investment LLC 目前拥有 224 股该生物技术公司的股票，价值 28,000 美元，此前在此期间又收购了 88 股。Concord Wealth Partners 在第二季度将其在 Biogen 股票中的持仓提高了 100.0%。Concord Wealth Partners 目前拥有 228 股该生物技术公司的股票，价值 29,000 美元，此前在此期间又收购了 114 股。NewSquare Capital LLC 在第二季度将其在 Biogen 股票中的持仓增加了 134.6%。NewSquare Capital LLC 目前拥有 244 股该生物技术公司的股票，价值 31,000 美元，此前在上个季度又购买了 140 股。最后，WFA of San Diego LLC 在第二季度购买了价值 32,000 美元的 Biogen 新股份。目前，87.93% 的股票由机构投资者持有。</p>
</div><h2>Biogen Price Performance</h2>
<div class="lb-trans"><h2>Biogen 价格表现</h2>
</div><p>BIIB stock opened at $174.80 on Friday. The stock has a market cap of $25.64 billion, a price-to-earnings ratio of 15.93, a P/E/G ratio of 1.47 and a beta of 0.13. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04. The company has a 50 day simple moving average of $163.65 and a 200 day simple moving average of $145.29. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $185.17.</p>
<div class="lb-trans"><p>BIIB 股票在周五开盘价为 174.80 美元。该股票的市值为 256.4 亿美元，市盈率为 15.93，市盈增长比率为 1.47，贝塔值为 0.13。该公司的债务与股本比率为 0.35，流动比率为 2.72，速动比率为 2.04。该公司的 50 日简单移动平均线为 163.65 美元，200 日简单移动平均线为 145.29 美元。Biogen Inc. 的一年低点为 110.04 美元，一年高点为 185.17 美元。</p>
</div><ul>
<li>These 3 Stocks Are Screaming Oversold: Seize the Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>这 3 只股票被严重低估：抓住机会</li>
</ul>
</div><p>Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, topping analysts' consensus estimates of $3.89 by $0.92. The firm had revenue of $2.53 billion for the quarter, compared to analysts' expectations of $2.34 billion. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The company's revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.08 earnings per share. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Research analysts anticipate that Biogen Inc. will post 15.83 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Biogen（NASDAQ:BIIB - 获取免费报告）最近在 10 月 30 日星期四发布了其财报。该生物技术公司报告本季度每股收益为 4.81 美元，超出分析师一致预期的 3.89 美元，超出幅度为 0.92 美元。该公司本季度的收入为 25.3 亿美元，而分析师预期为 23.4 亿美元。Biogen 的净利润率为 15.98%，股本回报率为 14.13%。该公司的收入同比增长 2.8%。在去年同期，该公司每股收益为 4.08 美元。Biogen 已将其 2025 财年的指导目标设定为每股收益 14.500-15.00。研究分析师预计 Biogen Inc. 本财年将发布每股收益 15.83。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages have issued reports on BIIB. HSBC reiterated a &#34;reduce&#34; rating and set a $143.00 price objective (down from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. Jefferies Financial Group upped their price target on shares of Biogen from $190.00 to $210.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 28th. Mizuho lifted their price objective on shares of Biogen from $169.00 to $177.00 and gave the company an &#34;outperform&#34; rating in a research note on Monday, November 3rd. Robert W. Baird lowered their price objective on shares of Biogen from $255.00 to $250.00 in a research report on Friday, October 31st. Finally, BMO Capital Markets raised their target price on Biogen from $150.00 to $165.00 and gave the company a &#34;market perform&#34; rating in a report on Thursday. Ten equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Biogen presently has a consensus rating of &#34;Hold&#34; and an average price target of $183.08.</p>
<div class="lb-trans"><p>多家券商对 BIIB 发布了报告。汇丰银行在 12 月 10 日的研究报告中重申了 &#34;减持&#34; 评级，并将 Biogen 股票的目标价设定为 143.00 美元（下调自 144.00 美元）。杰富瑞金融集团在 11 月 28 日的报告中将 Biogen 股票的目标价从 190.00 美元上调至 210.00 美元，并给予该股票 &#34;买入&#34; 评级。瑞穗证券在 11 月 3 日的研究报告中将 Biogen 股票的目标价从 169.00 美元上调至 177.00 美元，并给予该公司 &#34;跑赢大盘&#34; 评级。罗伯特·贝尔德在 10 月 31 日的研究报告中将 Biogen 股票的目标价从 255.00 美元下调至 250.00 美元。最后，BMO Capital Markets 在周四将 Biogen 的目标价从 150.00 美元上调至 165.00 美元，并给予该公司 &#34;市场表现&#34; 评级。十位股票研究分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Biogen 目前的共识评级为 &#34;持有&#34;，平均目标价为 183.08 美元。</p>
</div><ul>
<li>Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche</li>
</ul>
<div class="lb-trans"><ul>
<li>阿尔茨海默病药物股票：投资于 Eli Lilly、Biogen、Roche</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on Biogen</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Biogen 股票报告</strong></p>
</div><h2>About Biogen</h2>
<div class="lb-trans"><h2>关于 Biogen</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.</p>
<div class="lb-trans"><p>Biogen Inc 是一家跨国生物技术公司，专注于发现、开发和提供神经系统及神经退行性疾病的治疗方案。公司总部位于马萨诸塞州剑桥，长期以来专注于神经科学，研究和商业活动涵盖多种治疗领域，包括多发性硬化症、脊髓性肌萎缩症和阿尔茨海默病。Biogen 成立于 1978 年，已发展成为一家全球生物制药公司，在北美、欧洲、日本及其他国际市场拥有业务和商业存在。</p>
</div><p>The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.</p>
<div class="lb-trans"><p>该公司的市场产品组合历史上包括几种知名的多发性硬化症治疗药物，如 Avonex、Tysabri 和 Tecfidera，并且还在追求针对罕见神经疾病和遗传性神经肌肉疾病的治疗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Biogen</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Biogen 更好</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>这 3 家银行正在年末反弹，但这种趋势会持续吗？</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>3 只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>3 家杂货股票证明它们仍然是必需品</li>
<li>该 ETF 在美联储降息后获得了重大顺风</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BIIB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 BIIB 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Biogen Inc.（NASDAQ:BIIB - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=BIIB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Biogen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Biogen 吗？</h2>
</div><p>Before you consider Biogen, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Biogen 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Biogen 并不在名单上。</p>
</div><p>While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biogen 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Fluent Financial LLC 对 Biogen 公司进行了新的投资，股票代码为$BIIB